Hotline 24/7: 0909384389

Share links:

CRT 2019: Evolut R superior to surgery at one year in intermediate-risk patients

Ngày 16/03/2019 09:32 | Lượt xem: 1773

A subanalysis from the SURTAVI trial has found that transcatheter aortic valve implantation (TAVI) with Evolut R in intermediate-risk patients has lower rates of all-cause mortality or disabling stroke than surgical valve replacement 12 months after implantation. Steven J Yakubov (Riverside Methodist Hospital, Columbus, Ohio, USA) presented data from a propensity-score matched comparison at a late-breaking trial session at Cardiovascular Research Technologies (CRT) 2019 (2–5 March, Washington DC, USA). The findings have also been published in the Journal of American College of Cardiology: Cardiovascular Interventions.

He said: “All-cause mortality or disabling stroke, at one year, were less with TAVI compared to surgical aortic valve replacement. The transcatheter replacement group had less aortic valve or heart failure hospitalisations and less atrial fibrillation than the surgical replacement group at one year, and there was more need for permanent pacemaker implantation in the transcatheter group.”

The randomised SURTAVI trial demonstrated that TAVI using a self-expanding valve is non-inferior to surgical aortic valve replacement for the primary endpoint of all-cause mortality or disabling stroke at two years in patients at intermediate risk. Yakubov explained: “The Evolut R device was approved by the FDA as SURTAVI was enrolling patients; as a result, CoreValve was implanted in 84% of the patients in the transcatheter arm of the study, with only the remaining 16% receiving Evolut R. A continued access study was initiated after SURTAVI was fully enrolled to allow analysis of transcatheter implantation using the Evolut R device in intermediate-risk patients.”

The aim of the SURTAVI propensity score matched analysis was to compare one-year outcomes with Evolut R in intermediate-risk patients to those from a comparable surgical replacement cohort. Propensity matching on 22 variables allowed comparison between 197 Evolut R patients and 197 SURTAVI participants who underwent surgery. Average age was 79 years, and 40% of patients were male. Other matched variables included body mass index (BMI), New York Heart Association (NYHA) classification III/IV, need for revascularisation, peripheral vascular disease, and diabetes controlled by insulin.

At 12 months, combined all-cause mortality and disabling stroke on a Kaplan-Meier analysis were 4.1% (95% confidence interval [CI] 1.8–9.3) in the Evolut R patients vs. 8.2% (95% CI 5.1–13.1, p=0.08) among patients who had had surgery. Disabling stroke rates alone were 1% (95% CI 0.2–5.6) and 3.1% (95% CI 1.3–6.9, p=0.15), respectively, and there were less aortic valve hospitalisations using Evolute R (4.6% vs. 3.8% with surgery, p=0.33). In other clinical outcomes, the percentage of atrial fibrillation in patients receiving Evolute R was almost half that of those who underwent surgery (18.2% vs. 37.4%, p<0.01), and permanent pacemaker implantation rates were doubled (Evolut R 15.3%, surgery 7.8%, p=0.02).

Additionally, said Yakubov: “Evolut R demonstrated excellent haemodynamic performance. It had significantly better valve performance over surgery at all follow-up visits—baseline, discharge, six months, and one year [P<0.01].”

Among patients implanted with Evolut R, 61.2% experienced either no or trace aortic regurgitation (core lab adjudicated) and 32.9% had mild regurgitation; surgiwith 92% of surgical patients having no or trace regurgitation and 7.9% experiencing mild aortic regurgitation.

Evolut R also performed favourably on the outcomes of all-cause mortality and disabling stroke in a comparison of the propensity score matched analysis against the main SURTAVI trial—Evolut R 4.1% versus all TAVI 7.8% and all surgical replacement 8.5%.

Yakubov concluded: “The results for Evolut R TAVI were achieved compared to a propensity-score matched surgical group that had low STS [Society of Thoracic Surgery risk] scores. Advancements in catheter design technology may help drive greater success for intermediate-risk patients with severe, symptomatic aortic stenosis.”

Source CardioVascularNews

Duc Tin Clinic

Tin tức liên quan

Vesteck completes first-in-human use of several Suture-Tight devices

Age is just a number: Individual patient data meta-analysis probes safety of CEA in the elderly

Artificial intelligence can predict risk of complications after endovascular aneurysm repair

Bluegrass Vascular announces Journal of Vascular Surgery paper reporting use of Surfacer system

Vascular access creation: EndoAVF keeps future options open, but is not a replacement for surgical fistulas

SUPPORT CONSULTANT

CUSTOMER REVIEWS

• I am Nguyen Thanh Sang, born in 1990. Since the examination and treatment at the clinic Duc Tin, I am very grateful to the Doctor for explaining and sharing about my illness. During the treatment time in the clinic I was very caring staff of the clinic. Now my illness has improved in a good way. Expect more and more clinic to be able to save many patients.

  I sincerely thank you !. Tel: 0938303275

• Huynh Thi Muoi, born in 1940, was examined and treated at Duc Tin Clinic. I am very pleased about how to serve and care patients of the clinic. The doctor is committed to explaining and sharing with the patient.

  Huynh Thi Muoi sincerely thank you! Phone number: 0972868746

• As I said Duc Tin surgical clinin is where my family trust, hope to visit. Physicians caring, thoughtful, gentle to the patient. Nurses and staff clinic polite, cheerful and thoughtful. This clinic clean, sterile, so I would love to. Tel: +84949914060.

• The doctor is very caring, attentive and very gentle nurse, courteous, affable with me. The clinic is clean, comfortable, polite. I enjoyed this faith. Every visit I was very relieved disease. Tel: 0839820792.

• I was patient, had to clinics of Dr. Le Duc Tin. I see very conscientious doctor patient care, answer any questions and very dedicated staff from the receptionist to the children tested, nursing. Clinics very clean and spacious. I'm very satisfied. Tel: +841227880829.

Search

News

Customer support